Article and Video CATEGORIES

Cancer Journey

Search By

ABOUT
Denise Brock

Denise has over 30 years of varying experience in the healthcare arena.  In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees.  She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.  

 

Lung Cancer Video Library - Spanish Language: Video #17 First Line Therapy for NSCLC Patients That Have Anaplastic Lymphoma Kinase (ALK) Positive
Terapia de primera línea para pacientes con cáncer pulmonar de células no pequeñas que presentan la cinasa de linfoma anaplásico (CLA) positiva.
Author
Denise Brock
 

For our 17th video in the GRACE Spanish Lung Cancer Library, Dr. Brian Hunis, Medical Director, Head and Neck Cancer Program, Memorial Cancer Institute, Miami, Florida, joined GRACE to discuss the basics of Lung Cancer for Spanish-speaking patients and caregivers.  In this video Dr. Hunis speaks about first line therapy for non-small cell lung cancer patients that have anaplastic lymphoma kinase (ALK) positive.

 


 

TRANSCRIPTS - Spanish and English
 

Terapia de primera línea para pacientes con cáncer pulmonar de células no pequeñas que presentan la cinasa de linfoma anaplásico (CLA) positiva.

En los pacientes en los cuales uno describe que el adenocarcinoma de pulmón de células no pequeñas tiene la translocación del gen ALK, hay terapia dirigida que atacan exclusivamente a las células que expresan esa mutación. Por lo cual los efectos adversos, la toxicidad y las respuestas son muchísimo mejores.

La primera terapia para pacientes con translocación en ALK que se ha usado en el mundo es con crisotinib. Crisotinib es una píldora que se toma diariamente, es bien tolerada y con efectos muy positivos.


First line therapy for non-small cell lung cancer patients that have the anaplastic lymphoma kinase positive.

In patients that have adenocarcinoma of non-small cells and also have the ALK gene translocation, there is a targeted treatment that only attacks the cell that express this mutation. So, the side effects, toxicity and the response are better.

The first therapy for patients with the ALK translocation that has been used in the world is with crisotinib. Crisotinib is a pill that is taken daily, is well tolerated and with very positive effects.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.
Image
Videoteca de Cáncer de Pulmon - 2025
Video
Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.
Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.